ISRCTN47583497 https://doi.org/10.1186/ISRCTN47583497

# Decreased time on mechanical ventilation when comparing analgesia-based sedation using remifentanil versus standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial.

**Submission date**
09/02/2005

**Recruitment status**
No longer recruiting

**Registration date**
09/02/2005

**Overall study status**
Completed

**Last Edited**
16/08/2011

**Condition category**
Surgery

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr Andrew Kirkham

**Contact details**
GlaxoSmithKline
Greenford Road
Greenford, Middlesex
United Kingdom
UB6 OHE

## Additional identifiers

**Protocol serial number**
USA30226

## Study information

### Scientific Title

### Study objectives
Not provided at time of registration

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration

### Study design
Randomised controlled trial

### Primary study design
Interventional

### Study type(s)
Treatment

### Health condition(s) or problem(s) studied
Medical or surgical patients requiring intensive care.

### Interventions
Comparing analgesia-based sedation using remifentanil versus standard hypnotic-based sedation for up to 10 days in intensive care unit patients. Titration of analgesia/sedation to achieve optimal sedation. Regular assessments of haemodynamics.

### Intervention Type
Drug

### Phase
Not Specified

### Drug/device/biological/vaccine name(s)
Remifentanil

### Primary outcome(s)
Not provided at time of registration

### Key secondary outcome(s))
Not provided at time of registration

### Completion date
30/06/2003

## Eligibility

### Key inclusion criteria

Critically ill patients requiring 3-10 days of mechanical ventilation.

**Participant type(s)**
Patient

**Healthy volunteers allowed**
No

**Age group**
Not Specified

**Sex**

**Key exclusion criteria**
Not provided at time of registration

**Date of first enrolment**
07/06/2002

**Date of final enrolment**
30/06/2003

# Locations

**Countries of recruitment**
United Kingdom

Austria

Belgium

Denmark

France

Germany

Greece

Iran

Netherlands

Portugal

United Arab Emirates

**Study participating centre**

**GlaxoSmithKline**
Greenford, Middlesex
United Kingdom
UB6 OHE

# Sponsor information

**Organisation**
GlaxoSmithKline

**ROR**
https://ror.org/01xsqw823

# Funder(s)

**Funder type**
Industry

**Funder Name**
GlaxoSmithKline (GSK)

**Alternative Name(s)**
GlaxoSmithKline plc., GSK plc., GlaxoSmithKline plc, GSK

**Funding Body Type**
Government organisation

**Funding Body Subtype**
For-profit companies (industry)

**Location**
United Kingdom

# Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

**Study outputs**

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|

| | | | | |
|---|---|---|---|---|
| Results article | Results | 01/06/2005 | Yes | No |